Coronavirus Disease Contact Tracing Outcomes and Cost, Salt Lake County, Utah, USA, March-May 2020.

COVID-19 SARS SARS-CoV-2 contact tracing coronavirus coronavirus disease respiratory infections severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 27 10 2021
medline: 25 11 2021
entrez: 26 10 2021
Statut: ppublish

Résumé

Outcomes and costs of coronavirus disease (COVID-19) contact tracing are limited. During March-May 2020, we constructed transmission chains from 184 index cases and 1,499 contacts in Salt Lake County, Utah, USA, to assess outcomes and estimate staff time and salaries. We estimated 1,102 staff hours and $29,234 spent investigating index cases and contacts. Among contacts, 374 (25%) had COVID-19; secondary case detection rate was ≈31% among first-generation contacts, ≈16% among second- and third-generation contacts, and ≈12% among fourth-, fifth-, and sixth-generation contacts. At initial interview, 51% (187/370) of contacts were COVID-19-positive; 35% (98/277) became positive during 14-day quarantine. Median time from symptom onset to investigation was 7 days for index cases and 4 days for first-generation contacts. Contact tracing reduced the number of cases between contact generations and time between symptom onset and investigation but required substantial resources. Our findings can help jurisdictions allocate resources for contact tracing.

Identifiants

pubmed: 34698628
doi: 10.3201/eid2712.210505
pmc: PMC8632199
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2999-3008

Références

Euro Surveill. 2020 Jun;25(23):
pubmed: 32553064
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Science. 2020 May 8;368(6491):
pubmed: 32234805
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e29-36
pubmed: 21725247
MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):847-849
pubmed: 32614809
Health Care Manag Sci. 2007 Dec;10(4):341-55
pubmed: 18074967
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Lancet Infect Dis. 2020 Oct;20(10):1105-1106
pubmed: 32559453
Emerg Infect Dis. 2021 Feb;27(2):352-359
pubmed: 33275874
PLoS One. 2020 Jun 8;15(6):e0234418
pubmed: 32511264
Ann Epidemiol. 2021 Jul;59:50-55
pubmed: 33894384
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
Jpn J Infect Dis. 2020 Nov 24;73(6):491-493
pubmed: 32611985
JMIR Mhealth Uhealth. 2020 Apr 7;8(4):e18936
pubmed: 32240973
Lancet Public Health. 2020 Aug;5(8):e452-e459
pubmed: 32682487
MMWR Morb Mortal Wkly Rep. 2021 Jul 27;70(30):1044-1047
pubmed: 34324480
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-1323
pubmed: 32941418
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32521222
Swiss Med Wkly. 2020 Mar 19;150:w20225
pubmed: 32191813
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH